For all the hype, psychedelics such as MDMA or psilocybin won’t succeed as a treatment or service line without substantial clinical support within behavioral health organizations. As recent ketamine-provider stumbles demonstrate, simply establishing access to and attempting to scale singular forms of treatment tend to lead to failure. Further, such treatment-specific ventures fail to address the …

Psychedelics Must Be Based in ‘Traditional Psychiatric’ Care Read More »

The FDA is looking to hammer out a new pathway for studying the use of psychedelic drugs to treat behavioral health conditions. Specifically, the agency recently released a new draft guidance for the clinical development of psychedelic drugs. Although psychedelic drugs have shown promise in treating various mental health and substance use disorders, researchers have …

FDA’s Draft Guidance for Psychedelic Research Could Pave Way for More Widespread Adoption Read More »

London-based COMPASS Pathways plc (Nasdaq: CMPS) has secured $285 million in private funding to advance the company toward offering psychedelics as a treatment for mental health conditions. The company appears to see a clear path toward FDA approval and has convinced several investors of the opportunity. COMPASS Pathways named 11 investment firms and hinted at …

COMPASS Pathways Signals Confidence in Psychedelics with $285M in Funding Read More »

What we do Cannabis-based medicines were rescheduled under UK law in 2018 allowing doctors to prescribe these treatments to patients for a wide range of conditions. We are interested in the evaluation and development of novel cannabinoid therapies targeting: 1) inflammation & cancer, with a current focus on pancreatic ductal adenocarcinoma (PDAC) and 2) acute/post-surgical, …

Medical Cannabis Research Group Read More »

Psychedelic drugs are experiencing something of a renaissance. It’s no longer a case of turning on, tuning in and dropping out, as the hippy mantra went in the 1960s. Tripping – whether on magic mushrooms, LSD or psychedelic toads – is now part of the global wellness industry. It’s a way to “find yourself” or deal with a mental health or spiritual …

New research identifies the most common physical and psychological side-effects of ayahuasca Read More »

New research is exploring whether psychedelic drugs, taken under strict medical supervision, might help in treating post-traumatic stress disorder, chronic pain, depression and obsessive-compulsive disorder. SciLine interviewed Dr. Jennifer Mitchell—a professor in the Departments of Neurology and Psychiatry & Behavioral Science in the School of Medicine at the University of California, San Francisco—to discuss what scientists …

Use of psychedelics to treat PTSD, OCD, depression and chronic pain—a researcher discusses recent trials, possible risks Read More »

A more mystical and insightful psychedelic drug experience may be linked to an enduring reduction in anxiety and depression symptoms, according to a new study. Researchers conducted a machine learning analysis of data from nearly 1,000 respondents to a survey about their previous non-clinical experiences with psychedelic drugs. The analysis suggests that individuals who scored the …

Mystical and insightful psychedelic experience may improve mental health Read More »

Researchers from the University of Cincinnati examined the post-treatment journals kept by participants in a 2014 smoking cessation study that found psychedelics were effective in helping some people quit smoking for years. In a new paper published in the Kennedy Institute of Ethics Journal, researchers analyzed the participants’ own words and found that psychedelics combined with …

Psychedelics may help people reinvent themselves Read More »